Compare Sana Biotechnology Inc (SANA) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Advanced Drainage Systems Inc — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Advanced Drainage Systems Inc trades at $125.32 (market cap $9.52B). The key difference: Advanced Drainage Systems Inc is far larger — about 11.4× Sana Biotechnology Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WMS | |
|---|---|---|
Market Cap | $836.71M | $9.52B |
Volume | 4,507,444 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $175.38 |
52-Week Low | $2.68 | $125.33 |
Enterprise Value | $749.96M | $11.12B |
Typical Hold Time | — | 43 Days |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
WMS (Advanced Drainage Systems) trades at $124.92, down 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news includes the release of its 2026 Sustainability Report and a declared dividend of $0.20 per share payable in September 2026.
The outlook is supported by consistent earnings beats and analyst consensus pointing to significant upside with a $188.70 price target. However, a projected negative net cash flow of -$473M for 2026 and bearish technical indicators present near-term risks. Investor sentiment is mixed amid institutional buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
